Can you share with us a specific patient who has had an ACS event and is post-PCI, and how you optimize CV risk reduction in the age of PCSK9-mediated LDL-C risk reduction and aggressive LDL-C lowering?

Can you share with us a specific patient who has had an ACS event and is post-PCI, and how you optimize CV risk reduction in the age of PCSK9-mediated LDL-C risk reduction and aggressive LDL-C lowering?

Get Credit

Can you share with us a specific patient who has had an ACS event and is post-PCI, and how you optimize CV risk reduction in the age of PCSK9-mediated LDL-C risk reduction and aggressive LDL-C lowering?

Created by

CMEducation Resources IQ&A Cardiovascular Intelligence Zone | The Medical and Preventive Cardiologist's Perspective

Presenter

Dan Atar, MD

Dan Atar, MD

Head of Research Oslo University Hospital Ulleval Professor of Cardiology University of Oslo Oslo, Norway Visiting Associate Professorship Johns Hopkins University Baltimore, Maryland